Johns Hopkins scientists develop nose spray DNA vaccine for tuberculosis
A new intranasal DNA vaccine may give the immune system an extra weapon against tuberculosis by targeting bacteria that can hide from antibiotics. In animal studies, it helped clear infections faster, reduced lung inflam
Researchers at Johns Hopkins University have developed a novel DNA vaccine administered via nose spray for the prevention and treatment of tuberculosis. This approach leverages the immune system's ability to recognize and target bacteria that can evade antibiotics. The vaccine's efficacy was demonstrated in animal studies, where it accelerated infection clearance, decreased lung inflammation, and reduced the likelihood of relapse following treatment. Additionally, the vaccine was shown to enhance the effectiveness of existing drugs against drug-resistant tuberculosis. The development of this intranasal DNA vaccine represents a promising therapeutic strategy for combating tuberculosis, particularly in regions where antibiotic resistance is a significant concern. However, further research is needed to confirm its safety and efficacy in humans. The use of this vaccine should not be considered as a replacement for established treatment protocols, but rather as a potential adjunctive therapy. The authors acknowledge that the results of animal studies may not directly translate to human outcomes, and caution should be exercised when interpreting these findings in a clinical setting.